Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 6/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16330693 | 0.93 | HIF1A (0.53) | HIF1APAX8MEN1KMT2AADK | |
| SCHEMBL16330724 | 0.92 | HIF1A (0.60) | HIF1APAX8ADKTMEM97SIGMAR1 | |
| SCHEMBL16330685 | 0.88 | HIF1A (0.45) | HIF1APAX8MEN1KMT2AADK | |
| SCHEMBL16330754 | 0.87 | HIF1A (0.51) | HIF1APAX8MEN1KMT2AADK | |
| SCHEMBL16330723 | 0.84 | HIF1A (0.63) | HIF1APAX8ADKTMEM97SIGMAR1 | |
| SCHEMBL16330699 | 0.83 | ADK (0.44) | HIF1APAX8ADKPRMT5 | |
| SCHEMBL16330765 | 0.82 | HIF1A (0.54) | HIF1APAX8MEN1KMT2AADK | |
| SCHEMBL16330727 | 0.82 | HIF1A (0.46) | HIF1APAX8ADKTMEM97SIGMAR1 | |
| SCHEMBL16330757 | 0.81 | HIF1A (0.53) | HIF1APAX8MEN1KMT2AADK | |
| SCHEMBL16330760 | 0.81 | HIF1A (0.49) | HIF1APAX8ADKTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | HIF1A 922/4885PAX8 3693/4885MEN1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.